Clinical Trial Update: A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of Ad-RTS-hIL-12 with Veledimex in metastatic breast cancer was terminated and results have been posted. The trial was sponsored by Alaunos Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ad-RTS-hIL-12 (Adenoviral vector encoding human interleukin-12 under Rheostatic Transcriptional System)
• Veledimex (Veledimex; small-molecule activator of the RheoSwitch Therapeutic System)

Snippet

Sponsor: Alaunos Therapeutics | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-08-28